抗BCMA药物belantamab mafodotin治疗多发性骨髓瘤的关键研究达到主要终点

2019-08-26 Allan MedSci原创

葛兰素史克近日宣布,实验性药物belantamab mafodotin治疗复发/难治多发性骨髓瘤患者的关键性研究(DREAMM-2试验)符合其主要终点,患者对belantamab mafodotin的总体反应率(ORR)较高。

葛兰素史克近日宣布,实验性药物belantamab mafodotin治疗复发/难治多发性骨髓瘤患者的关键性研究(DREAMM-2试验)符合其主要终点,患者对belantamab mafodotin的总体反应率(ORR)较高。

Belantamab mafodotin,也称为GSK2857916,是一种免疫缀合物,其包含人源化抗BCMA单克隆抗体、接头和细胞毒性剂auristatin F。药物接头技术由Seattle Genetics许可。今年早些时候,GlaxoSmithKline报道了DREAMM-1研究的最新结果,证实了复发/难治多发性骨髓瘤患者对belantamab mafodotinORR60%。


原始出处:

http://www.firstwordpharma.com/node/1661304?tsid=4#axzz5xf7rqWhf

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1890050, encodeId=8dd61890050cd, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Dec 21 16:00:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996954, encodeId=1aa419969541d, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jun 15 04:00:00 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912198, encodeId=b71e1912198ca, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Sep 22 21:00:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969476, encodeId=07a019694e6cc, content=<a href='/topic/show?id=16675504ec5' target=_blank style='color:#2F92EE;'>#抗BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55047, encryptionId=16675504ec5, topicName=抗BCMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Thu Mar 19 17:00:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460220, encodeId=f997146022008, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3278, encryptionId=833732e80d, topicName=BCMA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f46265562, createdName=yykkxiaodou, createdTime=Wed Aug 28 00:00:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371863, encodeId=d7553e186356, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Aug 27 12:31:46 CST 2019, time=2019-08-27, status=1, ipAttribution=)]
    2019-12-21 jml2009
  2. [GetPortalCommentsPageByObjectIdResponse(id=1890050, encodeId=8dd61890050cd, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Dec 21 16:00:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996954, encodeId=1aa419969541d, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jun 15 04:00:00 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912198, encodeId=b71e1912198ca, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Sep 22 21:00:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969476, encodeId=07a019694e6cc, content=<a href='/topic/show?id=16675504ec5' target=_blank style='color:#2F92EE;'>#抗BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55047, encryptionId=16675504ec5, topicName=抗BCMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Thu Mar 19 17:00:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460220, encodeId=f997146022008, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3278, encryptionId=833732e80d, topicName=BCMA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f46265562, createdName=yykkxiaodou, createdTime=Wed Aug 28 00:00:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371863, encodeId=d7553e186356, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Aug 27 12:31:46 CST 2019, time=2019-08-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1890050, encodeId=8dd61890050cd, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Dec 21 16:00:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996954, encodeId=1aa419969541d, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jun 15 04:00:00 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912198, encodeId=b71e1912198ca, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Sep 22 21:00:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969476, encodeId=07a019694e6cc, content=<a href='/topic/show?id=16675504ec5' target=_blank style='color:#2F92EE;'>#抗BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55047, encryptionId=16675504ec5, topicName=抗BCMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Thu Mar 19 17:00:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460220, encodeId=f997146022008, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3278, encryptionId=833732e80d, topicName=BCMA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f46265562, createdName=yykkxiaodou, createdTime=Wed Aug 28 00:00:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371863, encodeId=d7553e186356, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Aug 27 12:31:46 CST 2019, time=2019-08-27, status=1, ipAttribution=)]
    2019-09-22 snf701207
  4. [GetPortalCommentsPageByObjectIdResponse(id=1890050, encodeId=8dd61890050cd, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Dec 21 16:00:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996954, encodeId=1aa419969541d, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jun 15 04:00:00 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912198, encodeId=b71e1912198ca, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Sep 22 21:00:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969476, encodeId=07a019694e6cc, content=<a href='/topic/show?id=16675504ec5' target=_blank style='color:#2F92EE;'>#抗BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55047, encryptionId=16675504ec5, topicName=抗BCMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Thu Mar 19 17:00:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460220, encodeId=f997146022008, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3278, encryptionId=833732e80d, topicName=BCMA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f46265562, createdName=yykkxiaodou, createdTime=Wed Aug 28 00:00:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371863, encodeId=d7553e186356, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Aug 27 12:31:46 CST 2019, time=2019-08-27, status=1, ipAttribution=)]
    2020-03-19 FukaiBao
  5. [GetPortalCommentsPageByObjectIdResponse(id=1890050, encodeId=8dd61890050cd, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Dec 21 16:00:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996954, encodeId=1aa419969541d, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jun 15 04:00:00 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912198, encodeId=b71e1912198ca, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Sep 22 21:00:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969476, encodeId=07a019694e6cc, content=<a href='/topic/show?id=16675504ec5' target=_blank style='color:#2F92EE;'>#抗BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55047, encryptionId=16675504ec5, topicName=抗BCMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Thu Mar 19 17:00:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460220, encodeId=f997146022008, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3278, encryptionId=833732e80d, topicName=BCMA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f46265562, createdName=yykkxiaodou, createdTime=Wed Aug 28 00:00:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371863, encodeId=d7553e186356, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Aug 27 12:31:46 CST 2019, time=2019-08-27, status=1, ipAttribution=)]
    2019-08-28 yykkxiaodou
  6. [GetPortalCommentsPageByObjectIdResponse(id=1890050, encodeId=8dd61890050cd, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Dec 21 16:00:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996954, encodeId=1aa419969541d, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jun 15 04:00:00 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912198, encodeId=b71e1912198ca, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Sep 22 21:00:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969476, encodeId=07a019694e6cc, content=<a href='/topic/show?id=16675504ec5' target=_blank style='color:#2F92EE;'>#抗BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55047, encryptionId=16675504ec5, topicName=抗BCMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Thu Mar 19 17:00:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460220, encodeId=f997146022008, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3278, encryptionId=833732e80d, topicName=BCMA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85f46265562, createdName=yykkxiaodou, createdTime=Wed Aug 28 00:00:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371863, encodeId=d7553e186356, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Aug 27 12:31:46 CST 2019, time=2019-08-27, status=1, ipAttribution=)]
    2019-08-27 1ddf0692m34(暂无匿称)

    学习了,谢谢分享

    0

相关资讯

Blood:放射元素At-211或可消除MM的微小残留病灶

微小残留病(MRD)在多发性骨髓瘤(MM)中日益普遍和重要。虽然对一线治疗的反应不断加深,但大约75%的MM患者从未取得MRD阴性(≤10-5);MRD阴性状态预示患者存活期长。MM具有高度异质性,MRD持续存在提示患者体内有分离的单细胞和小簇对治疗耐药的亚克隆存在。几乎所有的MM克隆都对放疗敏感;释放α射线的砹-211(211At)在三细胞直径范围内可释放大量的能量,如果可以有效的靶向,则会是消

Blood:PHF19通过增强PRC2来促进MM的发生发展

近期,研究人员发现PRC2相关因子,PHD手指蛋白19(PHF19)是多发性骨髓瘤(MM)肿瘤发生过程中的重要介质。现已发现PHF19过表达或遗传扩增与MM和浆细胞白血病患者的恶性进展相关。采用多种MM模型,研究人员证实PHF19对肿瘤细胞在体内外的生长都至关重要,

NEJM:XPOVIO(Selinexor)治疗难治性多发性骨髓瘤的IIb期STORM研究

Karyopharm是一家专注于肿瘤学的制药公司,近日宣布,XPOVIO(Selinexor)治疗难治性多发性骨髓瘤患者的IIb期STORM研究结果已经发表于《新英格兰医学杂志》。

强生向FDA提交申请寻求批准其抗CD38单抗DARZALEX皮下制剂治疗多发性骨髓瘤

强生制药公司今天宣布向美国食品和药物管理局(FDA)提交生物制剂许可证申请(BLA),寻求批准其DARZALEX(daratumumab)皮下制剂,用于治疗多发性骨髓瘤患者。

II期GRIFFIN研究结果:达雷妥尤单抗联合来那度胺、硼替佐米和地塞米松治疗初治多发性骨髓瘤

II期GRIFFIN(MMY2004)研究的最新结果显示,符合自体干细胞移植(ASCT)的初治多发性骨髓瘤患者使用达雷妥尤单抗联合来那度胺、硼替佐米和地塞米松(D-VRd)治疗,达到了该项试验的主要终点:D-VRd组的严格完全反应(sCR)显著高于VRd组(42.4% vs 32.0%)。

苏格兰医药联盟积极推荐Darzalex作为多发性骨髓瘤的二线治疗方案

强生公司近日宣布,苏格兰医药联盟(SMC)积极推荐使用Darzalex®(daratumumab,达雷妥尤单抗)联合硼替佐米和地塞米松作为多发性骨髓瘤的二线治疗方案。